Vericel Corporation Reports 30.1% Revenue Growth to $68.4 Million in Q1 2026

Vericel Corporation reported a significant increase in financial performance for the first quarter of 2026, with total revenue reaching $68.4 million, a 30.1% increase from $52.6 million in the same period of 2025. The growth was primarily driven by strong sales of its MACI and Epicel products, which saw revenue increases of 21.8% and 119.3%, respectively. The company reported a gross profit of $49.3 million, up 35.8% from $36.3 million a year earlier. Despite these gains, Vericel recorded a net loss of $6.3 million, an improvement from the $11.2 million loss reported in the prior year.

In terms of operational metrics, Vericel's product sales were bolstered by the expansion of its MACI product line, which includes the recently launched MACI Arthro instruments. The company has seen increased adoption of MACI, with over 900 surgeons participating in training programs for the new arthroscopic delivery method. The total number of shares outstanding as of April 30, 2026, was 51,068,228, reflecting ongoing stock-based compensation activities that contributed to a total shareholders' equity of $356.2 million.

Strategically, Vericel has made significant advancements, including a ten-year agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $196.9 million. This agreement aims to procure NexoBrid and establish a vendor-managed inventory system, among other initiatives. The company also received FDA approval to begin commercial manufacturing of MACI at its Burlington facility, which is expected to enhance production capabilities for both MACI and Epicel.

Vericel's liquidity position remains strong, with cash and cash equivalents totaling $109.3 million as of March 31, 2026. The company generated $16.4 million in cash from operating activities during the quarter, a notable increase from $6.6 million in the same period last year. The company anticipates that its current cash reserves, along with expected product sales, will be sufficient to support operations for at least the next 12 months. However, management noted that if revenues decline significantly, additional capital may be required, which could impact shareholder rights.

Looking ahead, Vericel is focused on expanding its market presence, particularly with MACI's potential use in treating ankle cartilage defects, which could significantly increase its addressable market. The company is also evaluating opportunities for international expansion, including obtaining regulatory approval for MACI in the United Kingdom. Overall, Vericel's strategic initiatives and product innovations position it for continued growth in the biopharmaceutical sector.